Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Related Resources
View All ResourcesApp Note: FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development
Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Webinar: BPI Digital Week 2018
Watch a 1-hour webinar from the 2018 BioProcess International Digital Week titled, “Implementing the Beacon Platform for the Next Generation of Cell Line Development,” featuring scientists from Berkeley Lights and Catalent Biologics.
Webinar: Bring Product Quality Assessment into Early Clone Selection with Opto™ Cell Line Development
CHO cell line selection represents a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. At BPI Europe Digital Week 2021, Renee Tobias discussed how the Opto™ CLD workflow on the Beacon® system can help through accelerating early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process.